Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICH: Pembrolizumab and Induction Chemotherapy in HNSCC
NCT03114280Phase 2Withdrawn
- Sponsor
- Centre Antoine Lacassagne
- Start
- Mar 2019
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Centre Antoine Lacassagne. Primary endpoints: Recommended dose for phase II and Progression-free survival. Planned start Mar 2019; status: withdrawn.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03114280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114280.